The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).
 
Guillermo de Velasco
Employment - GlaxoSmithKline (I)
Consulting or Advisory Role - Pierre Fabre
 
Diana Miao
No Relationships to Disclose
 
Sachet Shukla
No Relationships to Disclose
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Bayer; Calithera Biosciences; GlaxoSmithKline; Natera; Novartis
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Novartis
 
Catherine Wu
No Relationships to Disclose
 
Bradley Murray
No Relationships to Disclose
 
Matthew Meyerson
No Relationships to Disclose
 
Sabina Signoretti
No Relationships to Disclose
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Eliezer Mendel Van Allen
Consulting or Advisory Role - Roche; Syapse
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (Inst); GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)